Blood-Based Biomarkers for Brain Injury Assess Severity

Blood-Based Biomarkers for Brain Injury Detect Hidden Damage

Glial fibrillary acidic protein (GFAP) measured in blood within 24 hours of injury distinguishes acute traumatic brain injury (TBI) from uninjured tissue. Researchers led by the University of Pittsburgh School of Medicine evaluated two blood-based biomarkers for brain injury to triage patients who present with negative head computed tomography (CT) scans.

The study, published in the Journal of Neurosurgery, analyzed data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) multicenter study. In the United States, approximately 2.8 million individuals sustain a TBI annually, yet traditional emergency department (ED) assessments frequently miss subtle intracranial tissue damage.

Standard Computed Tomography Scans Miss One in Four Abnormalities

Standard head CT scans miss intracranial pathologies in approximately 25 percent of patients with traumatic brain injury. Those patients test normal on a CT scan but show abnormal tissue pathology when examined on magnetic resonance imaging (MRI).

MRIs provide detailed imaging of brain tissue, but the machines remain too slow and expensive for emergency triage. Earlier TRACK-TBI findings showed that over 50 percent of participants with mild TBI experience functional limitations at one year, indicating that undetected structural changes cause long-term deficits.

Glial Fibrillary Acidic Protein Outperformed Neuronal Markers

Glial fibrillary acidic protein identified patients with acute brain injury across multiple imaging categories, while ubiquitin c-terminal hydrolase-L1 (UCH-L1) demonstrated less diagnostic utility. GFAP is released by glial cells directly into the circulation following structural trauma.

Blood levels of GFAP show a rapid spike between 4 and 20 hours after injury, followed by a slow decline over subsequent days. The marker successfully distinguished patients with positive CT scans from those with negative scans, as well as patients with normal CT scans who had positive MRI findings.

Bedside Testing Enables Fifteen-Minute Triage in Emergency Settings

A whole-blood point-of-care version of the protein test delivers results at the patient bedside in 15 minutes. This platform allows emergency clinicians to evaluate tissue status without sending samples to an off-site laboratory.

The primary emergency application remains determining whether an initial CT scan is necessary for mild presentations. Establishing specific clinical cutoff values enables clinicians to escalate care and arrange specialized follow-up appointments for individuals who would otherwise receive an unmonitored discharge.

• Point-of-care tests use whole blood at the bedside rather than waiting for central laboratory processing.
• Results return in approximately 15 minutes to guide emergency triage decisions.
• Established thresholds identify patients who require outpatient neurological monitoring despite clear scans.

Clinical Limitations and Metabolic Context for Brain Recovery

The diagnostic window for GFAP depends heavily on the timing of blood collection relative to the trauma event. Because protein levels peak between 4 and 20 hours and decline thereafter, delayed presentation to an emergency facility can skew interpretation.

Physical impacts cause immediate cellular stress, which alters glial cell integrity and brain glucose regulation during recovery. Individuals who sustain an impact should consult a qualified clinician regarding persistent symptoms such as brain fog, headache, or fatigue, even when initial emergency scans report normal findings.